Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576571 | 1.00 | PDGFRB (0.57) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL18163409 | 0.84 | PDGFRA (0.57) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29577001 | 0.84 | PDGFRA (0.57) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL24292886 | 0.82 | PDGFRB (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL30106509 | 0.81 | MET (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL371742 | 0.81 | MET (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29576979 | 0.80 | PDGFRB (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL4400367 | 0.79 | PDGFRB (0.72) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL22703596 | 0.79 | KDR (0.52) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL198505 | 0.78 | PDGFRB (0.68) | PDGFRBPDGFRAFGFR2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520416-B | Polysubstituted pyridone derivative, preparation method and medical application thereof | 北京越之康泰生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-110041316-B | TAM family kinase/CSF 1R kinase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20210163448-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | QURIENT CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
| EP-3741752-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741752-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| CN-110520416-A | Polysubstituted pyridine ketones derivant, preparation method and its medical usage | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD | 2019-11-29 | — | — | CN | disclosed |
| WO-2019141202-A9 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019141202-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | CSF1R, CSF3R, FLT3 | PDGFRB 93/4885PDGFRA 111/4885FGFR2 442/4885 |
| US-20210163448-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | CSF1R, CSF3R, FLT3 | PDGFRB 31/4885PDGFRA 41/4885FGFR2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.